ABOS

$2.17+$0.06 (+2.84%)prev close

Compare

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institution

Market cap

$156.7M

72M shares

52-week range

$1.19 – $3.60

41% from low

Sector

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Exchange

NASDAQ

Change$-13.10

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$0	—	$-1.42	$-1.71–$-1.11	—	3
2027	$0	—	$-1.46	$-2.27–$-0.68	—	3
2028	$4M	—	$-1.17	$-1.77–$-0.58	—	2
2029	$56M	+1353.4%	$-0.73	$-0.73–$-0.73	—	1

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 4 of the last 8 reported quarters

Reported	Est. EPS	Actual	Surprise
2026-05-12	$-0.40	$-0.33	+18.1%
2026-03-26	$-0.50	$-0.41	+18.0%
2025-11-12	$-0.63	$-0.44	+30.2%
2025-08-12	$-0.54	$-0.68	-25.9%
2025-05-13	$-0.56	$-0.48	+14.3%
2025-03-27	$-0.47	$-0.62	-31.9%
2024-11-12	$-0.36	$-0.50	-38.9%
2024-08-13	$-0.28

DCF fair valuemodel estimate

Intrinsic value

$0.38

Price

$2.17

Implied downside

-83%

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
ABOSAcumen Pharmaceuticals, Inc.	$2.17	+2.84%	$157M	—
ACTUActuate Therapeutics Inc	$1.17	+8.33%	$28M	—
AGENAgenus Inc.	$7.91	+19.31%	$329M	—
ALECAlector, Inc.	$1.62	+6.58%	$180M	—
FATEFate Therapeutics, Inc.	$2.51	+6.36%

Acumen Pharmaceuticals, Inc. Common Stock

Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.

www.acumenpharm.com

Employees: 61
IPO / List date: Jul 1, 2021
HQ: NEWTON, MA

Held by traders on TradeandTell

No one on the platform currently holds ABOS.

Super investors & insiders

Institutions holding (13F)

Institution	Shares	Reported
Renaissance Technologiesas of 2026-03-31	473,946	$1.1M

Insider activity (SEC Form 4)

Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded ABOS yet.

$ABOS chatter on StockTwits

CE@selftaughtJul 22
$ABOS Watching again!
View on StockTwits ↗
PRISM MarketView@prismmarketviewJul 16
( $ABOS) @AcumenPharm is pushing its EBD™ bispecifics to the front of the AD pipeline: ACU401 delivered up to 40x higher frontal‑cortex exposure in primates with no anemia signals, setting up low‑volume subQ dosing in early Alzheimer’s just as ALTITUDE‑AD patient data highlight how urgently better brain‑penetrant therapies are needed. https://prismmarketview.com/companies/acumen-pharmaceuticals-inc/
View on StockTwits ↗
PRISM MarketView@prismmarketviewJul 15
$ABOS Acumen Pharmaceuticals just dropped new brain-delivery data at #AAIC2026. Its EBD candidate ACU401 hit up to 40x greater frontal cortex exposure in primates — with no anemia safety signals. A big step for its Alzheimer's pipeline. 🧠 #Alzheimers #Biotech #NASDAQ #ABOS https://prismmarketview.com/acumen-pharmaceuticals-advances-brain-delivery-platform-with-new-aaic-2026-data/
View on StockTwits ↗
Go for ProMIS@GoforProMISBullishJul 2
$PMN $ABOS Platform companies can achieve significantly higher market valuations than only Alzheimer targeting companies as Acumen! WHAT would it take for ProMIS to really take off? The market would need to become convinced that: * PMN310 is at least as effective as existing Alzheimer’s antibodies. * At the same time, it causes significantly less ARIA. * EpiSelect genuinely identifies disease-specific epitopes, including for alpha-synuclein and TDP-43. * Preclinical programs successfully advance to clinical trials. * A major pharmaceutical partner validates the platform through a collaboration or licensing agreement. In that case, ProMIS would no longer be valued merely as a company with a single Alzheimer’s project, but as a platform company with several blockbuster targeting diseases!
View on StockTwits ↗
Go for ProMIS@GoforProMISBullishJul 2
$PMN $ABOS Direct competitive comparison: Investment Risk Analysis 1. PMN: Comfortable time buffer, but a costly future. The good news: Thanks to the major PIPE financing in February 2026, PMN is funded well into 2027. They will not need to execute an emergency capital raise immediately upon the release of data—whether the interim analysis in early Q3 2026 or the topline data in early 2027. 2. ABOS: More cash, but a tighter timeframe. The good news: With over $128 million in the bank, ABOS possesses greater financial firepower in absolute terms than PMN. Furthermore, its Phase 2 trial (542 patients) is already significantly larger and more robust. PMN represents the slightly more "comfortable" investment for the next 12 to 15 months, as its funds last beyond the final data readout in early 2027. Acumen, on the other hand, has the more fundamentally advanced project but faces immense pressure to deliver immediately by the end of 2026, as its funds will run out shortly thereafter.
View on StockTwits ↗
Jamere Cedric@Johndoe456BullishJun 30
$ABOS
View on StockTwits ↗
pir@SannieVerraderlijkJun 19
$ABOS $CCCC $NKTR $RLMD $ SABS $ ZURA Some longs added to Russell 3000 yesterday
View on StockTwits ↗
jorge .miguel@focafoca99Jun 17
$ABOS captured a strategic partnership as Acumen exercised its exclusive option to develop Alzheimer’s therapies using J‑Brain Cargo
View on StockTwits ↗
Jeff Siegel@LibertarianTreehuggerJun 16
Acumen Advances Two New Alzheimer's Drug Candidates Designed to Reach the Brain More Effectively: https://jlsfund.substack.com/p/acumen-advances-two-new-alzheimers $ABOS
View on StockTwits ↗
DARKP00L@DARKP00LJun 16
$ABOS 07:43 on Jun. 16 2026 Acumen Pharmaceuticals Nominates Two Development Candidates In Its Enhanced Brain Delivery Program For Alzheimer's Disease Treatments, IND Submission Expected In Mid-2027 #tradeideas
View on StockTwits ↗
jorge .miguel@focafoca99Jun 16
$ABOS announces nomination of two enhanced brain delivery candidates for Alzheimer’s disease under its JCR collaboration.
View on StockTwits ↗
ELITE_MOMENTUM_TRADING@Stock_CatcherBullishJun 16
$ABOS Acumen Pharmaceuticals Announces Nomination of Two Enhanced Brain Delivery™ (EBD™) Development Candidates for the Treatment of Alzheimer’s Disease
View on StockTwits ↗
Mitersaw@Mitersaw1BullishMay 21
$ABOS
View on StockTwits ↗
Mitersaw@Mitersaw1May 20
$ABOS
View on StockTwits ↗
David Smith@Stockley_BulbousberriesBullishMay 20
$ABOS
View on StockTwits ↗

Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.